Inotersen vs Nucresiran

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Transthyretin Amyloidosis with Polyneuropathy

Shared mechanism: Transthyretin (TTR) · full Transthyretin Amyloidosis with Polyneuropathy pipeline

Inotersen · Tegsedi

Rights held by Ionis Pharmaceuticals and partners

US approval withdrawn in Transthyretin Amyloidosis with Polyneuropathyantisense
Reliable signal

NCT01737398 · Phase 2/3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial in 172 patients. Both co-primary endpoints, a validated neuropathy impairment score and a quality-of-life questionnaire, showed statistically significant benefit with inotersen versus placebo at week 66.

No aligned efficacy figure on record for this race.

Nucresiran

Developed by Alnylam Pharmaceuticals

Phase 3 in Transthyretin Amyloidosis with PolyneuropathyRNAi
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT07223203 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Transthyretin Amyloidosis with Polyneuropathy

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Inotersen: registry results are on file for Transthyretin Amyloidosis with Polyneuropathy, but their comparison mappings are not yet available.

Nucresiran: no structured comparison results are available for Transthyretin Amyloidosis with Polyneuropathy.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Inotersen's landscape · Nucresiran's landscape